Biomarkers of vascular disease in scleroderma

Research output: Contribution to journalArticle

Abstract

Vascular disease is present in every patient with scleroderma and is a major source of morbidity and mortality. There is a subset of patients who will develop severe and sometimes life-threatening vascular events. We have good evidence that an insult to the microvasculature occurs early in the disease course, but there is a subset of patients who have an ongoing chronic process, the end result of which are events such as digital loss and pulmonary arterial hypertension. The ability to detect this process at an early stage by simple means would be of great value as our ability to treat these vascular complications improves with time. We have a significant amount of evidence of vascular perturbation from studies of peripheral blood in scleroderma, but know very little about the ability of these biomarkers to predict vascular outcomes. In this review, we will critically assess our current knowledge of the use of biomarkers of vascular disease in scleroderma and the possible directions of future research in this area.

Original languageEnglish (US)
JournalRheumatology
Volume47
Issue numberSUPPL. 5
DOIs
StatePublished - 2009

Fingerprint

Vascular Diseases
Blood Vessels
Biomarkers
Microvessels
Pulmonary Hypertension
Morbidity
Mortality

Keywords

  • Biomarkers
  • Diffusing capacity for carbon monoxide
  • N-terminal pro-BNP
  • Pulmonary hypertension
  • Scleroderma

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Biomarkers of vascular disease in scleroderma. / Hummers, Laura.

In: Rheumatology, Vol. 47, No. SUPPL. 5, 2009.

Research output: Contribution to journalArticle

@article{8e0eab6c9cb745d599c3770590789b35,
title = "Biomarkers of vascular disease in scleroderma",
abstract = "Vascular disease is present in every patient with scleroderma and is a major source of morbidity and mortality. There is a subset of patients who will develop severe and sometimes life-threatening vascular events. We have good evidence that an insult to the microvasculature occurs early in the disease course, but there is a subset of patients who have an ongoing chronic process, the end result of which are events such as digital loss and pulmonary arterial hypertension. The ability to detect this process at an early stage by simple means would be of great value as our ability to treat these vascular complications improves with time. We have a significant amount of evidence of vascular perturbation from studies of peripheral blood in scleroderma, but know very little about the ability of these biomarkers to predict vascular outcomes. In this review, we will critically assess our current knowledge of the use of biomarkers of vascular disease in scleroderma and the possible directions of future research in this area.",
keywords = "Biomarkers, Diffusing capacity for carbon monoxide, N-terminal pro-BNP, Pulmonary hypertension, Scleroderma",
author = "Laura Hummers",
year = "2009",
doi = "10.1093/rheumatology/ken281",
language = "English (US)",
volume = "47",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Biomarkers of vascular disease in scleroderma

AU - Hummers, Laura

PY - 2009

Y1 - 2009

N2 - Vascular disease is present in every patient with scleroderma and is a major source of morbidity and mortality. There is a subset of patients who will develop severe and sometimes life-threatening vascular events. We have good evidence that an insult to the microvasculature occurs early in the disease course, but there is a subset of patients who have an ongoing chronic process, the end result of which are events such as digital loss and pulmonary arterial hypertension. The ability to detect this process at an early stage by simple means would be of great value as our ability to treat these vascular complications improves with time. We have a significant amount of evidence of vascular perturbation from studies of peripheral blood in scleroderma, but know very little about the ability of these biomarkers to predict vascular outcomes. In this review, we will critically assess our current knowledge of the use of biomarkers of vascular disease in scleroderma and the possible directions of future research in this area.

AB - Vascular disease is present in every patient with scleroderma and is a major source of morbidity and mortality. There is a subset of patients who will develop severe and sometimes life-threatening vascular events. We have good evidence that an insult to the microvasculature occurs early in the disease course, but there is a subset of patients who have an ongoing chronic process, the end result of which are events such as digital loss and pulmonary arterial hypertension. The ability to detect this process at an early stage by simple means would be of great value as our ability to treat these vascular complications improves with time. We have a significant amount of evidence of vascular perturbation from studies of peripheral blood in scleroderma, but know very little about the ability of these biomarkers to predict vascular outcomes. In this review, we will critically assess our current knowledge of the use of biomarkers of vascular disease in scleroderma and the possible directions of future research in this area.

KW - Biomarkers

KW - Diffusing capacity for carbon monoxide

KW - N-terminal pro-BNP

KW - Pulmonary hypertension

KW - Scleroderma

UR - http://www.scopus.com/inward/record.url?scp=69949168097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949168097&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ken281

DO - 10.1093/rheumatology/ken281

M3 - Article

VL - 47

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - SUPPL. 5

ER -